Alx oncology announces new data from aspen-01, the phase 1b study of alx148, showing robust objective response in patients with gastric or gastroesophageal junction cancer

-- orr of 72% observed in patients with > 2l her2 positive gastric or gastroesophageal junction cancer -- estimated os at 12 months of 76% -- alx oncology to host conference call on july 6 th at 8:30 a.m. et

ALXO Ratings Summary

ALXO Quant Ranking